10-Q: Cardiff Oncology Faces Litigation, Seeks Funding

Cardiff Oncology's Q2 2026 report highlights ongoing litigation with NMS, substantial doubt about its going concern status, and a registered direct offering to raise capital, alongside promising clinical trial updates for onvansertib.

Summary

• Cardiff Oncology reported a net loss of $9.23 million for the three months ended June 30, 2026, and $21.58 million for the six months ended June 30, 2026.
• The company has substantial doubt about its ability to continue as a going concern, with current capital resources insufficient for the next 12 months.
• A significant legal dispute with Nerviano Medical Sciences (NMS) regarding a license agreement for onvansertib is ongoing, with both parties filing lawsuits.
• Cardiff Oncology completed a registered direct offering on July 14, 2026, raising $10.1 million in gross proceeds.
• Positive data from the Phase 2 trial of onvansertib in combination with chemotherapy for RAS-mutated metastatic colorectal cancer (mCRC) was presented, showing a 72.2% objective response rate.
• The company is preparing for a Phase 3 registrational trial for onvansertib in mCRC.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the ongoing litigation, substantial doubt about the company's ability to continue as a going concern, and significant net losses, despite positive clinical trial data.

Positives

• Positive clinical data from the Phase 2 trial of onvansertib in combination with FOLFIRI/bevacizumab for first-line RAS-mutated mCRC showed a 72.2% confirmed objective response rate, a 30% improvement over standard of care.
• The onvansertib 30 mg dose regimen demonstrated deep and durable tumor shrinkage with no additive adverse events.
• The company is on track with manufacturing and regulatory activities for the upcoming Phase 3 registrational trial (CRDF-005).
• Investigator-initiated trials in other indications like mPDAC, SCLC, mTNBC, and CMML are progressing, providing additional data on onvansertib's potential.
• Preclinical data suggests onvansertib may be effective in combination with HER2-targeted ADCs for HER2-low breast cancer.

Negatives

• The company has incurred net losses since inception and has negative operating cash flows.
• As of June 30, 2026, the company had $34.5 million in cash, cash equivalents, and short-term investments, which is not sufficient to meet funding requirements for at least the next 12 months, leading to substantial doubt about its ability to continue as a going concern.
• A significant legal dispute with NMS over a license agreement for onvansertib is ongoing, with NMS alleging material breach and attempting to terminate the agreement.
• The company filed a lawsuit against NMS seeking injunctive relief and declaratory judgment.
• The company's common stock purchase agreement with certain institutional investors and insiders on July 14, 2026, was at a purchase price of $1.05 per share for institutional investors and $1.455 for insiders, indicating a potentially depressed stock valuation.
• The company reported a net loss of $9.23 million for the three months ended June 30, 2026, and $21.58 million for the six months ended June 30, 2026.

Risks

• The ongoing litigation with NMS poses a significant risk; if NMS's termination of the agreement is upheld, Cardiff Oncology could lose rights to onvansertib, materially impacting its business.
• The company faces substantial doubt about its ability to continue as a going concern due to insufficient capital resources to fund operations for at least the next 12 months.
• The company may not be able to obtain or maintain permanent or preliminary injunctive relief in the litigation with NMS, potentially disrupting business operations.
• The litigation is costly, time-consuming, and could divert management attention and resources from core business activities.
• The pendency of the litigation could adversely affect the company's ability to raise additional capital or enter into strategic transactions.
• If the agreement termination is upheld, the company may be unable to obtain replacement license rights on acceptable terms.
• The outcome of litigation is inherently unpredictable and subject to appeal, creating prolonged uncertainty.
• The company's ability to continue as a going concern is dependent on its ability to obtain additional equity or debt financing, which cannot be guaranteed.

Future Outlook

The company expects its capital resources to fund operations into the third quarter of 2027, but this is not sufficient for at least the next 12 months, indicating a need for further financing. The company is preparing for a Phase 3 registrational trial for onvansertib in mCRC and is continuing to support investigator-initiated trials in other indications.

Management Comments

• The appointments of Dr. Mani Mohindru, Josh Muntner, and Dr. Ajay Aggarwal reflect our commitment to building an experienced leadership team to advance onvansertib and deliver on the programs long-term potential.
• Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern.
• The Company's ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing, obtain government grants or reduce expenditures.

Industry Context

StockSavvy.ai notes that Cardiff Oncology operates in the highly competitive and capital-intensive clinical-stage biotechnology sector. The company's focus on PLK1 inhibition for cancer treatment aligns with industry trends of targeted therapies. However, the significant legal dispute and going concern issues are critical factors that differentiate its risk profile from many peers.

Comparison to Industry Standards

• The objective response rate (ORR) of 72.2% for onvansertib + FOLFIRI/bev in first-line RAS-mutated mCRC is notably higher than typical ORRs for standard of care in this setting, which often range from 40-50%.
• The progression-free survival (PFS) hazard ratio of 0.55-0.57 suggests a significant improvement in delaying disease progression compared to standard of care, a key metric for industry approval.
• The company's net loss of $21.58 million for the first six months of 2026 is substantial, but not unusual for clinical-stage biotech companies investing heavily in R&D. However, the concurrent cash position raises concerns about runway compared to industry benchmarks for companies at this stage.
• The need for a registered direct offering at a relatively low price point ($1.05-$1.455) suggests potential market concerns about the company's financial stability and the litigation risk, which can impact valuation compared to peers with cleaner balance sheets and fewer legal entanglements.

Management Changes

Legal Proceedings

• Cardiff Oncology filed a lawsuit against NMS on May 19, 2026, seeking injunctive relief and declaratory judgment regarding the license agreement for onvansertib.
• NMS alleged material breach of the license agreement and purported to terminate the agreement on May 27, 2026, and filed counterclaims against Cardiff Oncology.
• The company is seeking preliminary injunctive relief to prevent NMS from terminating the agreement.

Stakeholder Impact

• Shareholders may experience dilution due to the recent registered direct offering and potential future equity issuances needed to fund operations.
• The ongoing litigation with NMS creates uncertainty for all stakeholders regarding the future of onvansertib and the company's operations.
• Employees may face uncertainty due to the going concern issues and the potential impact of the litigation on the company's long-term viability.

Next Steps

• Initiate the registrational Phase 3 trial (CRDF-005) for onvansertib in first-line RAS-mutated mCRC.
• Continue to support investigator-initiated trials in mPDAC, SCLC, mTNBC, and CMML.
• Seek stockholder approval for an amendment to the certificate of incorporation to increase the number of authorized shares of common stock to facilitate the exercise of warrants.
• Await decision on the motion for preliminary injunction in the litigation with NMS.

Key Dates

Recommendation

The company shows promising clinical data for its lead asset, onvansertib, particularly in mCRC. However, significant headwinds exist, including substantial doubt about its going concern status, a critical ongoing litigation with its licensor (NMS), and the need for further capital raises which could dilute existing shareholders. While the clinical progress is positive, the litigation and financial uncertainty warrant a cautious 'hold' stance until these risks are resolved or mitigated.

Keywords

onvansertib, PLK1 inhibitor, colorectal cancer, biotechnology, clinical trials, drug development, licensing agreement, litigation